SpectrumDNA Stock

SpectrumDNA EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of SpectrumDNA (SPXA) as of Jul 26, 2026.

EV/EBIT

-0.00

Last updated:

EV/EBIT (Enterprise Value to EBIT) of SpectrumDNA is 2026 -0.00 . EV/EBIT (Enterprise Value to EBIT) of SpectrumDNA was 2025 - . It decreases by % lower compared to the previous year.

The SpectrumDNA EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2006
0.00 base
Jan 1, 2007
0.00 base
Jan 1, 2008
0.00 base
Jan 1, 2009
0.00 base
Jan 1, 2010
0.00 base
YEARPRICE-TO-EBIT
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

SpectrumDNA Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides SpectrumDNA's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates SpectrumDNA's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots SpectrumDNA's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if SpectrumDNA grows earnings faster than its peers.

SpectrumDNA Stock analysis

What does SpectrumDNA do? SpectrumDNA Inc is a company specializing in the development and marketing of genetic tests and analyses. Founded in 2013, the company is based in Austin, Texas and is one of the leading companies in the field of DNA analysis. The history of SpectrumDNA goes back to its founders, Dr. Jamie Teumer and Dr. João Silveira. Both bring years of experience in genetics and molecular biology and have worked on numerous research projects. Their goal was to make genetics accessible to everyone and improve healthcare. With this drive, they founded SpectrumDNA and began to put their idea into action. SpectrumDNA's business model is based on the creation of genetic tests and analyses that allow people to know their personal risk for certain diseases or conditions and take targeted preventive measures. SpectrumDNA works closely with doctors and other healthcare experts to interpret and implement the results and recommendations of the tests. SpectrumDNA offers a variety of genetic tests and analyses targeting various areas of health and well-being. These include tests for identifying genetic risk factors for cancer, cardiovascular diseases, Alzheimer's, and Parkinson's, as well as tests for predicting behavioral traits and physical characteristics such as lactose intolerance or hair color. The company also has its own research and development department that constantly works on advancing and improving test methods and technologies. This ensures that customers at SpectrumDNA always receive the latest and most accurate information. SpectrumDNA has also specialized in developing products based on the genetic profiles of its customers. These include personalized supplements tailored to the individual needs of the customer, as well as personalized training plans based on the customer's genetic traits. Recently, SpectrumDNA has also focused its attention on the application of genetics in the beauty industry. The company has developed a procedure that allows the analysis of skin quality and aging process based on the customer's genetic profile. Based on this analysis, a personalized skincare program is created that is tailored to the individual needs and goals of the customer. Overall, SpectrumDNA is a leading company in the field of DNA analysis and specializes in personalized healthcare services. Through close collaboration with doctors and other healthcare providers, as well as constant advancement and improvement of its technologies and products, SpectrumDNA enables its customers to improve their health and well-being in a personalized and effective way. SpectrumDNA is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SpectrumDNA stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) SpectrumDNA since 2006 – with annual values, charts, and detailed analysis.

Access this data via the Eulerpool API

Valuation — SpectrumDNA

All Key Metrics — SpectrumDNA